Bionik Laboratories
BNKL · OTC
Price unavailable right now.
No price history for this range.
Key indicators
BNKL profitability and balance sheet ratios
EPS -$0.1944 in Mar 2023, against -$0.2883 a year earlier.
| Period | EPS |
|---|---|
| Jun 2021 | -$0.0791 |
| Sep 2021 | -$0.2165 |
| Dec 2021 | -$1.18 |
| Mar 2022 | -$0.2883 |
| Jun 2022 | -$0.2012 |
| Sep 2022 | -$0.1642 |
| Dec 2022 | -$0.1564 |
| Mar 2023 | -$0.1944 |
Income statement
No financial statements are reported for Bionik Laboratories.
Balance sheet
What the company owns and owes at period end
Total assets
Total liabilities
| Line item | Sep 2022 | Dec 2022 | Mar 2023 |
|---|---|---|---|
| Total assets | $3.8M | $3.7M | $3.4M |
| Total liabilities | $3.3M | $4.2M | $5.0M |
| Shareholder equity | $0.5M | −$0.5M | −$1.6M |
| Cash and short-term investments | $0.4M | $0.7M | $0.4M |
| Total debt | $0.8M | $1.6M | $2.2M |
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.